SCHEDULE 13G/A: BlackRock Reports 17.4% Passive Stake in Xencor Inc. Common Stock
Beneficial Ownership Report
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 17.4% beneficial ownership in Xencor Inc.'s common stock as of December 31, 2024.
Summary
- BlackRock, Inc. reported beneficial ownership of 12,201,617 shares of Xencor Inc. common stock.
- This ownership represents 17.4% of the total outstanding common stock of Xencor Inc.
- The filing, Amendment No. 5 to Schedule 13G, reflects the ownership position as of December 31, 2024.
- BlackRock holds sole voting power over 12,023,007 shares and sole dispositive power over all 12,201,617 beneficially owned shares.
- No shared voting or dispositive power was reported.
- One of BlackRock's entities, iShares Core S & P Small-Cap ETF, is noted to hold more than 5% of Xencor Inc.'s common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While a large institutional stake can be seen as a positive signal, a Schedule 13G is a routine passive ownership disclosure and does not imply active engagement or a change in investment thesis that would significantly alter the company's outlook.
Positives
- The significant stake held by BlackRock, a leading global asset manager, can be interpreted as a vote of confidence in Xencor Inc.'s long-term prospects by a major institutional investor.
- The filing provides transparency regarding the institutional ownership structure of Xencor Inc.
Future Outlook
This Schedule 13G filing is a disclosure of passive ownership and does not contain any forward-looking statements or guidance regarding Xencor Inc.'s future performance or BlackRock's investment strategy beyond the reported stake.
Industry Context
BlackRock, Inc. is one of the world's largest asset managers, and its significant stake in Xencor Inc. reflects its investment strategy, which often includes passive index tracking or active management across its diverse range of funds. Xencor Inc. operates in the biotechnology sector, specializing in the discovery and development of engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases.
Stakeholder Impact
- Shareholders: Increased transparency regarding institutional ownership, potentially signaling confidence from a major investor.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney revoked. |
| 2024-12-31 | Date of event which requires filing of this statement (ownership snapshot date). |
| 2025-01-21 | Date of execution of the current Power of Attorney by BlackRock, Inc. |
| 2025-02-05 | Date of filing of the Schedule 13G Amendment No. 5. |
Keywords
Xencor Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.